china
pass
world
health
organ
vaccin
regulatori
assess
approv
give
local
manufactur
green
light
enter
global
vaccin
market
march
state
china
state
food
drug
administr
sfda
compli
intern
standard
vaccin
regul
result
vaccin
come
china
imprimatur
intern
recognit
export
domest
sale
say
peicheng
liu
spokesperson
beij
sinovac
keep
intern
standard
may
erod
china
price
competit
process
obtain
approv
sfda
revis
indic
overal
vaccin
approv
framework
market
author
licens
postmarket
surveil
lot
releas
laboratori
access
regulatori
inspect
manufactur
site
distribut
channel
author
monitor
clinic
trial
complianc
sfda
intern
standard
first
step
process
see
chines
vaccin
produc
make
signific
contribut
meet
world
vaccin
need
near
futur
say
repres
china
michael
oleari
green
light
seen
import
chines
vaccin
industri
plagu
scandal
march
nearli
babi
shanxi
provinc
becam
sick
die
receiv
defect
vaccin
hepat
b
viru
rabi
viru
though
govern
deni
link
incid
follow
problem
substandard
rabi
vaccin
made
jiangsu
ealong
biotech
erod
public
confid
valid
chines
author
adher
standard
could
go
way
restor
public
confid
approv
enabl
chines
vaccin
maker
better
know
intern
norm
practic
definit
help
improv
vaccin
qualiti
domest
market
say
zixin
qiu
gener
manag
beij
wantai
produc
hecolin
world
first
vaccin
hepat
e
viru
hev
escherichia
recombin
fragment
hev
capsid
protein
alum
adjuv
china
nation
obtain
statu
trail
develop
countri
india
cuba
sfda
tri
unsuccess
obtain
approv
sever
time
past
xiaofeng
liang
director
nation
vaccin
offic
chines
centr
diseas
control
prevent
stress
approv
mean
china
wellregul
vaccin
industri
main
reason
china
reject
past
lack
postsal
surveil
system
vaccin
sideeffect
rare
vaccin
sideeffect
sometim
appear
vaccin
use
larger
gener
popul
european
medicin
agenc
us
food
drug
administr
requir
postmarket
surveil
vaccin
maker
fear
report
case
public
might
refus
take
vaccin
employe
one
china
largest
vaccin
maker
wish
remain
anonym
told
natur
biotechnolog
open
report
side
effect
like
remain
problem
system
set
complianc
voluntari
one
mani
domest
vaccin
maker
like
remain
reluct
collect
report
side
effect
vaccin
chines
watchdog
increas
regul
educ
improv
gener
industri
awar
insid
say
liu
sinovac
add
chines
vaccin
maker
familiar
intern
vaccin
purchas
long
road
sell
chines
vaccin
global
market
despit
lower
price
say
vaccin
made
china
inde
cheap
exampl
combin
measl
mump
rubella
vaccin
price
china
nation
develop
reform
commiss
yuan
per
price
approv
us
center
diseas
control
prevent
lowcost
vaccin
made
china
nation
biotec
group
headquart
beij
domest
market
meet
intern
standard
like
requir
expens
materi
current
employ
manufactur
say
wantai
qiu
suppli
vaccin
unit
nation
agenc
vaccin
maker
must
abid
china
new
version
good
manufactur
practic
gmp
releas
late
februari
new
gmp
stipul
stricter
requir
sanit
product
process
standard
line
requir
adopt
us
eu
china
nearli
pharma
ask
pass
new
gmp
approv
three
year
vaccin
maker
must
pass
five
year
lose
drug
product
licens
western
pharma
china
new
statu
present
interest
prospect
one
hand
opportun
exist
technolog
transfer
agreement
partnership
help
chines
manufactur
maintain
complianc
sfda
hand
china
could
gain
signific
market
share
develop
nation
vaccin
compani
merck
whitehous
station
new
jersey
glaxosmithklin
london
pfizer
new
york
novarti
basel
sanofi
pari
current
stranglehold
combin
vaccin
sale
billion
contact
natur
biotechnolog
execut
multin
vaccin
maker
reluct
specul
approv
might
influenc
busi
strategi
china
vaccin
manufactur
firm
go
forward
tabl
short
term
chines
manufactur
like
seek
help
foreign
firm
improv
oper
particularli
govern
begin
open
door
multin
corpor
geneva
intern
feder
pharmaceut
manufactur
associ
say
sfda
lower
barrier
entri
allow
foreign
invest
buyout
partnership
effort
improv
countri
capabl
western
pharmaceut
firm
china
domest
vaccin
market
attract
prospect
novarti
exampl
laid
million
march
pick
stake
biopharmaceut
locat
zhejiang
tianyuan
vaccin
maker
produc
season
inactiv
flu
vaccin
inactiv
bival
hemorrhag
fever
renal
syndrom
viru
vaccin
alum
adjuv
inactiv
japanes
enceph
viru
vaccin
quadrival
polysaccharidebas
vaccin
cover
four
pathogen
meningococc
serogroup
c
posit
signal
foreign
compani
investor
wish
follow
say
feng
li
senior
vice
presid
advanc
pharmaceut
technolog
transfer
consult
firm
base
raleigh
north
carolina
shanghai
might
opportun
get
foot
chines
market
glaxosmithklin
merck
believ
place
chines
manufactur
beyond
domest
market
emerg
nation
brazil
india
mexico
russia
turkey
two
year
ago
glaxosmithklin
join
chines
compani
shenzhen
neptunu
walvax
biotech
manufactur
influenza
vaccin
pediatr
vaccin
wherea
merck
sign
deal
sinopharm
group
affili
work
human
papilloma
viru
vaccin
believ
great
scienc
know
border
say
mark
feinberg
vice
presid
medic
affair
polici
merck
impress
strong
scientif
capabl
abund
china
chines
manufactur
may
help
improv
access
vaccin
develop
nation
prequalif
act
qualiti
assur
watchdog
lowincom
countri
lack
regulatori
process
sabin
haubenreiss
european
medicin
agenc
london
say
influenza
vaccin
suppli
pandem
bottleneck
china
could
potenti
facilit
suppli
global
demand
pandem
china
first
export
like
vaccin
japanes
enceph
viru
viru
current
whoprequalifi
vaccin
although
market
one
made
research
foundat
microbi
diseas
osaka
univers
biken
viennabas
intercel
distribut
sanofi
novarti
china
expect
prequalifi
vaccin
diseas
within
one
two
year
